<DOC>
	<DOCNO>NCT00403169</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth kidney cancer block blood flow tumor . PURPOSE : This phase II trial study well lenalidomide work treat patient advance unresectable kidney cancer .</brief_summary>
	<brief_title>Lenalidomide Treating Patients With Advanced Unresectable Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate best response patient advance unresectable renal cell carcinoma ( RCC ) treat lenalidomide . - Evaluate response duration , time tumor progression , survival patient advance RCC treat lenalidomide . - Evaluate safety drug patient . OUTLINE : This open-label study . Patients receive oral lenalidomide daily day 1-21 . Courses repeat every 28 day absence unacceptable toxicity disease progression . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm renal cell carcinoma ( RCC ) Advanced unresectable RCC Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No brain metastasis Brain metastasis treat either radiotherapy surgery remain asymptomatic , active brain metastasis , show CT scan MRI , ≥ 6 month allow PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN hepatic metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year , except treat basal cell squamous cell carcinoma skin , carcinoma situ cervix breast , localized prostate cancer , superficial bladder cancer No history allergic reaction attribute compound similar chemical biological composition lenalidomide thalidomide No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance No hepatitis A , B , C positivity No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No 1 prior systemic therapy RCC ( e.g. , chemotherapy , hormonal therapy , immunotherapy ) At least 4 week since prior surgery , radiotherapy , hormonal therapy , chemotherapy , immunotherapy recover No prior lenalidomide No concurrent anticancer agent treatments No concurrent investigational agent No concurrent sargramostim ( GMCSF ) , radiotherapy , thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>